American Flag
JULY 4TH SALE

50% off your first year of Quiver Premium

...

Use Promo Code:

JULY4
Upgrade
American Flag

Teva Pharmaceutical Industries Limited American Depositary Shares

TEVA Real Time Price USD
16.75
-0.10
(-0.59%)
As of today at 09:36 UTC-04:00
Add to Watchlist
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of TEVA by members of U.S. Congress

Politician Type Traded
Greg Gianforte House / R Purchase $15,001 - $50,000 Nov 13, 2020
Donna E. Shalala House / D Sale $1,001 - $15,000 May 07, 2020
David E. Price House / D Sale $1,001 - $15,000 Jun 19, 2019
Thad Cochran Senate / R Purchase $15,001 - $50,000 Feb 12, 2018
Patty Murray Senate / D Sale (Full) $1,001 - $15,000 Jun 15, 2017
Thad Cochran Senate / R Sale (Full) $1,001 - $15,000 May 30, 2017
Thad Cochran Senate / R Purchase $1,001 - $15,000 Mar 17, 2017
Thad Cochran Senate / R Purchase $1,001 - $15,000 Mar 14, 2017
Cheri Bustos House / D Sale $1,001 - $15,000 Jan 30, 2017
Angus S. King Jr. Senate / I Sale (Full) $1,001 - $15,000 Oct 19, 2016
Thad Cochran Senate / R Sale (Full) $1,001 - $15,000 Sep 29, 2016
K. Michael Conaway House / R Sale $1,001 - $15,000 Sep 12, 2016
Thad Cochran Senate / R Purchase $15,001 - $50,000 Jun 01, 2016
K. Michael Conaway House / R Sale $1,001 - $15,000 May 11, 2016
K. Michael Conaway House / R Sale $1,001 - $15,000 May 04, 2016
Thad Cochran Senate / R Sale (Full) $1,001 - $15,000 Feb 02, 2016
Alan S. Lowenthal House / D Sale $15,001 - $50,000 Sep 11, 2015
Alan S. Lowenthal House / D Sale $15,001 - $50,000 Jul 27, 2015
K. Michael Conaway House / R Sale $1,001 - $15,000 Feb 09, 2015
Michael T. McCaul House / R Sale $15,001 - $50,000 Feb 01, 2015
Michael T. McCaul House / R Sale $15,001 - $50,000 Feb 01, 2015
Thomas MacArthur House / R Sale $1,001 - $15,000 Jan 27, 2015
Thomas MacArthur House / R Purchase $1,001 - $15,000 Jan 06, 2015
Alan S. Lowenthal House / D Purchase $15,001 - $50,000 Dec 19, 2014
Alan S. Lowenthal House / D Purchase $15,001 - $50,000 Dec 12, 2014
K. Michael Conaway House / R Sale $1,001 - $15,000 Mar 12, 2014
K. Michael Conaway House / R Purchase $1,001 - $15,000 Mar 06, 2014
TEVA Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
TEVA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
TEVA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Whales2.333333333New0Increased1Held4Decreased1Closed1
Insider Trading

Quarterly net insider trading by TEVA's directors and management

2024Q32024Q42025Q12025Q22025Q3−400k−350k−300k−250k−200k−150k−100k−50k0
Net Shares Purchased by Insiders

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $2,050,000 Apr 20, 2022 Issue: Health Issues
  • $80,000 Apr 20, 2022 Issue: Health Issues
  • $60,000 Apr 20, 2022 Issue: Pharmacy Medicare/Medicaid Health Issues
  • $80,000 Apr 11, 2022 Issue: Pharmacy Health Issues
  • $60,000 Jan 24, 2022 Issue: Medicare/Medicaid Health Issues
  • $80,000 Jan 20, 2022 Issue: Health Issues
  • $600,000 Jan 20, 2022 Issue: HEALTH ISSUES
  • $80,000 Jan 13, 2022 Issue: Pharmacy Health Issues
  • $700,000 Oct 25, 2021 Issue: HEALTH ISSUES
  • $810,000 Oct 25, 2021 Issue: HEALTH ISSUES
  • $60,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues
  • $80,000 Oct 18, 2021 Issue: Health Issues
  • $80,000 Oct 11, 2021 Issue: Pharmacy Health Issues
  • $80,000 Jul 19, 2021 Issue: Health Issues
  • $50,000 Jul 16, 2021 Issue: Medicare/Medicaid Health Issues
  • $80,000 Jul 12, 2021 Issue: Pharmacy Health Issues
  • $50,000 Apr 20, 2021 Issue: Health Issues
  • $50,000 Apr 20, 2021 Issue: Health Issues Medicare/Medicaid
  • $1,820,000 Apr 20, 2021 Issue: HEALTH ISSUES
  • $30,000 Apr 12, 2021 Issue: None
  • $80,000 Apr 12, 2021 Issue: Pharmacy Health Issues
  • $50,000 Jan 21, 2021 Issue: Health Issues
  • $610,000 Jan 21, 2021 Issue: HEALTH ISSUES
  • $80,000 Jan 14, 2021 Issue: Pharmacy Health Issues
  • $80,000 Jan 13, 2021 Issue: Health Issues Pharmacy
  • $40,000 Oct 20, 2020 Issue: Health Issues
  • $500,000 Oct 19, 2020 Issue: HEALTH ISSUES
  • $80,000 Oct 15, 2020 Issue: Pharmacy Health Issues
  • $80,000 Oct 12, 2020 Issue: Health Issues Pharmacy
  • $580,000 Jul 16, 2020 Issue: None
  • $80,000 Jul 13, 2020 Issue: Pharmacy Health Issues
  • $30,000 Jul 07, 2020 Issue: Pharmacy Health Issues
  • $430,000 Apr 20, 2020 Issue: None
  • $80,000 Apr 14, 2020 Issue: Pharmacy Health Issues
  • $30,000 Apr 07, 2020 Issue: Pharmacy Health Issues
  • $410,000 Jan 21, 2020 Issue: None
  • $75,000 Jul 11, 2019 Issue: Pharmacy Health Issues
  • $30,000 Jul 05, 2019 Issue: Medicare/Medicaid Health Issues Pharmacy
  • $740,000 Jun 25, 2019 Issue: Health Issues Trade (domestic/foreign)
  • $30,000 Apr 09, 2019 Issue: Health Issues Medicare/Medicaid Pharmacy
  • $700,000 Jan 21, 2019 Issue: Health Issues
  • $1,130,000 Jul 20, 2018 Issue: Health Issues
  • $90,000 Apr 30, 2018 Issue: Pharmacy
  • $480,000 Apr 20, 2018 Issue: Health Issues
  • $20,000 Apr 20, 2018 Issue: Pharmacy Medicare/Medicaid Health Issues
  • $10,000 Apr 19, 2018 Issue: Health Issues Alcohol and Drug Abuse
  • $40,000 Mar 21, 2018 Issue: None
  • $50,000 Feb 08, 2018 Issue: Health Issues Medicare/Medicaid
  • $40,000 Jan 22, 2018 Issue: Health Issues Alcohol and Drug Abuse
  • $880,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code
  • $90,000 Jan 21, 2018 Issue: Pharmacy
  • $60,000 Jan 18, 2018 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Health Issues Pharmacy
  • $50,000 Oct 27, 2017 Issue: Health Issues Medicare/Medicaid
  • $105,000 Oct 23, 2017 Issue: Pharmacy
  • $1,200,000 Oct 19, 2017 Issue: Health Issues Taxation/Internal Revenue Code
  • $60,000 Oct 19, 2017 Issue: Pharmacy Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $40,000 Oct 19, 2017 Issue: Alcohol and Drug Abuse Health Issues
  • $50,000 Aug 08, 2017 Issue: Health Issues Medicare/Medicaid
  • $60,000 Jul 20, 2017 Issue: Pharmacy Health Issues Taxation/Internal Revenue Code Government Issues Medicare/Medicaid
  • $840,000 Jul 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code
  • $40,000 Jul 19, 2017 Issue: Alcohol and Drug Abuse Health Issues
  • $50,000 May 08, 2017 Issue: Medicare/Medicaid Health Issues
  • $40,000 Apr 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code
  • $2,670,000 Apr 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code
  • $105,000 Apr 20, 2017 Issue: Pharmacy
  • $50,000 Apr 19, 2017 Issue: Alcohol and Drug Abuse Health Issues
  • $1,170,000 Jan 31, 2017 Issue: Pharmacy Trade (domestic/foreign) Copyright/Patent/Trademark
  • $30,000 Jan 27, 2017 Issue: Pharmacy
  • $60,000 Jan 19, 2017 Issue: Health Issues Alcohol and Drug Abuse
  • $50,000 Jan 18, 2017 Issue: Medicare/Medicaid Health Issues
  • $105,000 Jan 17, 2017 Issue: Pharmacy
  • $30,000 Feb 09, 2016 Issue: Pharmacy
  • $50,000 Feb 03, 2016 Issue: Health Issues
  • $45,000 Jan 28, 2016 Issue: Pharmacy
  • $45,000 Jan 28, 2016 Issue: Pharmacy
  • $105,000 Jan 20, 2016 Issue: Pharmacy
  • $60,000 Jan 20, 2016 Issue: Health Issues Labor Issues/Antitrust/Workplace Alcohol and Drug Abuse
  • $900,000 Jan 20, 2016 Issue: Trade (domestic/foreign) Copyright/Patent/Trademark Pharmacy
  • $105,000 Oct 21, 2015 Issue: Pharmacy
  • $60,000 Oct 20, 2015 Issue: Labor Issues/Antitrust/Workplace Alcohol and Drug Abuse Health Issues
  • $50,000 Oct 20, 2015 Issue: Health Issues
  • $990,000 Oct 19, 2015 Issue: Pharmacy Trade (domestic/foreign) Copyright/Patent/Trademark
  • $45,000 Jul 23, 2015 Issue: Pharmacy
  • $60,000 Jul 20, 2015 Issue: Alcohol and Drug Abuse Health Issues
  • $980,000 Jul 16, 2015 Issue: Pharmacy Trade (domestic/foreign)
  • $105,000 Jul 16, 2015 Issue: Pharmacy
  • $50,000 Jul 16, 2015 Issue: Health Issues
  • $10,000 Jul 13, 2015 Issue: Pharmacy
  • $45,000 Apr 27, 2015 Issue: Pharmacy
  • $50,000 Apr 20, 2015 Issue: Health Issues
  • $60,000 Apr 20, 2015 Issue: Alcohol and Drug Abuse Health Issues
  • $105,000 Apr 20, 2015 Issue: Pharmacy
  • $1,200,000 Apr 19, 2015 Issue: Trade (domestic/foreign) Pharmacy
  • $890,000 Jan 20, 2015 Issue: Pharmacy Trade (domestic/foreign)
  • $880,000 Oct 20, 2014 Issue: Pharmacy Trade (domestic/foreign)
  • $870,000 Jul 21, 2014 Issue: Pharmacy Trade (domestic/foreign) Copyright/Patent/Trademark
  • $1,160,000 Apr 18, 2014 Issue: Pharmacy Copyright/Patent/Trademark Trade (domestic/foreign)
  • $800,000 Jan 17, 2014 Issue: Pharmacy Copyright/Patent/Trademark Trade (domestic/foreign)
  • $810,000 Oct 21, 2013 Issue: Pharmacy Copyright/Patent/Trademark Tariff (miscellaneous tariff bills) Trade (domestic/foreign)
  • $820,000 Jul 22, 2013 Issue: Tariff (miscellaneous tariff bills) Pharmacy Copyright/Patent/Trademark Trade (domestic/foreign)
Corporate Lobbying

Estimated quarterly lobbying spending

20212022050k100k150k200k250k300k
Q4Q3Q2Q1Lobbying Amount
Revenue Breakdown

TEVA Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
TEVA Income Statement
TEVA Balance Sheet
TEVA Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Medical injection device packaging May. 09, 2023
  • Patent Title: S1p3 antagonists Oct. 18, 2022
  • Patent Title: Injector pen Nov. 23, 2021
  • Patent Title: Medroxyprogesterone acetate injectable compositions and methods of use Oct. 05, 2021
  • Patent Title: Re-useable injector device for syringe Mar. 19, 2019
  • Patent Title: Analogs of pridopidine, their preparation and use Nov. 20, 2018
  • Patent Title: Re-useable injector device for syringe Sep. 11, 2018
  • Patent Title: Injector pen Aug. 28, 2018
  • Patent Title: S1p3 antagonists Apr. 24, 2018
  • Patent Title: Re-useable injector device for syringe Nov. 28, 2017
  • Patent Title: Process for manufacturing glatiramer acetate product Sep. 19, 2017
  • Patent Title: Process for manufacturing glatiramer acetate product Jul. 18, 2017
  • Patent Title: Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis Jun. 27, 2017
  • Patent Title: Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status May. 30, 2017
  • Patent Title: Dose counter and recording method Apr. 18, 2017
  • Patent Title: Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate Apr. 18, 2017
  • Patent Title: Biomarkers predictive for clinical response for glatiramer acetate Apr. 11, 2017
  • Patent Title: Respiratory apparatus Apr. 11, 2017
  • Patent Title: Respiratory apparatus Apr. 11, 2017
  • Patent Title: Respiratory apparatus Apr. 11, 2017
  • Patent Title: Respiratory apparatus Apr. 11, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Apr. 04, 2017
  • Patent Title: Respiratory appartus Apr. 04, 2017
  • Patent Title: Respiratory apparatus Mar. 28, 2017
  • Patent Title: Respiratory apparatus Mar. 28, 2017
  • Patent Title: Respiratory apparatus Mar. 28, 2017
  • Patent Title: Respiratory apparatus Mar. 28, 2017
  • Patent Title: Respiratory apparatus Mar. 28, 2017
  • Patent Title: Respiratory apparatus Mar. 28, 2017
  • Patent Title: Respiratory apparatus Mar. 28, 2017
  • Patent Title: Treatment of bdnf-related disorders using laquinimod Mar. 07, 2017
  • Patent Title: Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate Nov. 22, 2016
  • Patent Title: Formulations of albu-bche, preparation and uses thereof Aug. 09, 2016
  • Patent Title: Formulations of 6-mercaptopurine Jun. 28, 2016
  • Patent Title: R(+)-n-formyl-propargyl-aminoindan May. 24, 2016
  • Patent Title: Stable laquinimod preparations May. 17, 2016
  • Patent Title: R(+)-n-methyl-propargyl-aminoindan May. 17, 2016
  • Patent Title: Parenteral formulations of rasagiline Apr. 12, 2016
  • Patent Title: N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof Mar. 15, 2016
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

2021202205M10M15M20M25M30M35M
Q4Q3Q2Q1Government Contracts Amount
TEVA News

Recent insights relating to TEVA

Teva Pharmaceutical Industries Ltd. to Announce Second Quarter 2025 Financial Results on July 30, 20256/25/2025, 8:40:35 PMArticle Thumbnail
Teva Pharmaceutical Industries Presents Final Analysis of PEARL Study Demonstrating Sustained Effectiveness of AJOVY in Migraine Prevention at EAN 2025 Congress6/23/2025, 7:10:18 AMArticle Thumbnail
Leader Capital Markets Remains a Buy on Teva (TEVA)6/21/2025, 11:55:08 AMArticle Thumbnail
New Insider Disclosure: Kalif Eliyahu Sharon (EVP, Chief Financial Officer) disclosed 55775 shares sold of $TEVA6/16/2025, 8:16:00 PMArticle Thumbnail
New Insider Disclosure: Shields Matthew (EVP, Global Operations) disclosed 6206 shares sold of $TEVA6/5/2025, 9:16:00 PMArticle Thumbnail
Teva Pharmaceutical Industries Ltd. Announces Early Tender Results and Increased Tender Caps for Note Offers6/3/2025, 11:20:39 AMArticle Thumbnail
Teva Pharmaceuticals Highlights Critical Treatment Gaps for Tardive Dyskinesia in Long-Term Care Facilities5/31/2025, 1:10:37 AMArticle Thumbnail
Teva Pharmaceuticals Reports Positive Real-World Outcomes for UZEDY® (risperidone) in Schizophrenia Treatment Compared to Second-Generation Oral Antipsychotics5/31/2025, 1:10:37 AMArticle Thumbnail
Teva Pharmaceutical Industries Ltd. Announces Acceleration Plan to Transform into a Leading Biopharma Company by 20305/29/2025, 12:13:24 PMArticle Thumbnail
Teva Pharmaceutical Industries Receives FDA Fast Track Designation for TEV-53408 in Celiac Disease Treatment5/27/2025, 9:40:20 PMArticle Thumbnail
Teva Pharmaceutical Increases Maximum Tender Amount and Pool Tender Caps in Tender Offer Announcement5/22/2025, 6:00:40 PMArticle Thumbnail
Teva Pharmaceuticals Receives Credit Rating Upgrade to BB+ from Fitch Ratings5/20/2025, 8:41:38 PMArticle Thumbnail
Teva Pharmaceutical Industries Ltd. Plans $2 Billion Senior Notes Offering to Finance Debt Tender Offers5/19/2025, 9:01:12 AMArticle Thumbnail
Teva Pharmaceutical Industries Ltd. Launches Tender Offers for $2 Billion in Senior Notes to Optimize Debt Structure5/19/2025, 9:01:12 AMArticle Thumbnail
Teva Pharmaceuticals Achieves Credit Rating Upgrade from Moody's to Ba1, Outlook Stable5/15/2025, 10:20:33 PMArticle Thumbnail
New Insider Disclosure: Sabag Mark (See "Remarks") disclosed 337915 shares sold of $TEVA5/12/2025, 8:16:00 PMArticle Thumbnail
Fund Update: Phoenix Financial Ltd. Just Disclosed New Holdings5/7/2025, 12:51:10 PMArticle Thumbnail
Fund Update: Harel Insurance Investments & Financial Services Ltd. Just Disclosed New Holdings4/29/2025, 11:53:06 AMArticle Thumbnail
New Insider Disclosure: Daniell Richard (Exec. VP, European Commercial) disclosed 70961 shares sold of $TEVA3/7/2025, 9:17:00 PMArticle Thumbnail
New Insider Disclosure: Francis Richard D (President and CEO) disclosed 23773 shares sold of $TEVA3/6/2025, 9:17:00 PMArticle Thumbnail
New Insider Disclosure: Hughes Eric A (See "Remarks") disclosed 23251 shares sold of $TEVA3/6/2025, 9:17:00 PMArticle Thumbnail
New Insider Disclosure: Daniell Richard (Exec. VP, European Commercial) disclosed 140372 shares sold of $TEVA3/6/2025, 9:17:00 PMArticle Thumbnail
New Insider Disclosure: Hughes Eric A (See "Remarks") disclosed 24900 shares sold of $TEVA3/5/2025, 9:17:00 PMArticle Thumbnail
New Insider Disclosure: Daniell Richard (Exec. VP, European Commercial) disclosed 62250 shares sold of $TEVA3/5/2025, 9:17:00 PMArticle Thumbnail
Teva Pharmaceuticals and Alvotech Announce U.S. Launch of SELARSDI™ Biosimilar for Autoimmune Diseases2/21/2025, 11:11:24 AMArticle Thumbnail
Alvotech and Teva Pharmaceuticals Announce FDA Acceptance of Biologics License Application for AVT06 Biosimilar to Eylea®2/18/2025, 11:13:15 AMArticle Thumbnail
Teva Pharmaceuticals and Klinge Biopharma GmbH Collaborate for Global Commercialization of FYB203 Biosimilar Candidate to Eylea®1/13/2025, 6:10:21 AMArticle Thumbnail
Samsung Bioepis and Teva Pharmaceutical Enter Partnership for EPYSQLI® Biosimilar to Enhance Treatment Options for Rare Disease Patients in the U.S.1/10/2025, 1:42:59 PMArticle Thumbnail
Teva Pharmaceutical Industries Ltd. to Release Q4 and Full Year 2024 Financial Results on January 29, 202512/20/2024, 9:40:45 PMArticle Thumbnail
Teva and Sanofi Announce Phase 2b Study Success for Duvakitug in Treating Ulcerative Colitis and Crohn's Disease12/17/2024, 12:41:18 PMArticle Thumbnail
CNBC Recommendations

Recent picks made for TEVA stock on CNBC

PersonalityTypeDate
Steve GrassoFinal Trade02/21/2025
Jim CramerBullish03/22/2024
Jim CramerSell02/22/2023
Jim CramerSell07/28/2022
Jim CramerBearish05/05/2022
Top ETF Holders

ETFs with the largest estimated holdings in TEVA

ETFEst. Holding Size
IEFAiShares Core MSCI EAFE ETF$125 million
EFAiShares MSCI EAFE ETF$66 million
EFViShares MSCI EAFE Value ETF$35 million
IXUSiShares Core MSCI Total International Stock ETF$26 million
EISiShares MSCI Israel ETF$21 million
SPDWSPDR Portfolio Developed World ex-US ETF$18 million
IDEViShares Core MSCI International Developed Markets ETF$16 million
FNDFSchwab Fundamental International Equity ETF$11 million
PPHVanEck Pharmaceutical ETF$9.6 million
EFGiShares MSCI EAFE Growth ETF$9.4 million
IVLUiShares MSCI Intl Value Factor ETF$9.2 million
DBEFXtrackers MSCI EAFE Hedged Equity ETF$8 million
ISRAVanEck Israel ETF$7.4 million
BINCiShares Flexible Income Active ETF$7.3 million
BINCiShares Flexible Income Active ETF$6.5 million
BINCiShares Flexible Income Active ETF$5.7 million
ACWIiShares MSCI ACWI ETF$5.2 million
DFAIDimensional International Core Equity Market ETF$4.4 million
ACWXiShares MSCI ACWI ex U.S. ETF$4.2 million
DIHPDimensional International High Profitability ETF$4.1 million
AVDEAvantis International Equity ETF$4.1 million
BINCiShares Flexible Income Active ETF$3.6 million
BINCiShares Flexible Income Active ETF$3.1 million
DFAXDimensional World ex U.S. Core Equity 2 ETF$2.8 million
GSIEGoldman Sachs ActiveBeta International Equity ETF$2.6 million
DFICDimensional International Core Equity 2 ETF$2.3 million
BINCiShares Flexible Income Active ETF$2.2 million
IZRLARK Israel Innovative Technology ETF$2.1 million
PXFInvesco RAFI Developed Markets ex-U.S. ETF$1.8 million
FMILFidelity New Millennium ETF$1.6 million
FFLCFidelity Fundamental Large Cap Core ETF$1.6 million
URTHiShares MSCI World ETF$1.3 million
CWISPDR MSCI ACWI ex-US ETF$1.2 million
BINCiShares Flexible Income Active ETF$930 thousand
APIEActivePassive International Equity ETF$781 thousand
QEFASPDR MSCI EAFE StrategicFactors ETF$731 thousand
MNTLTema Neuroscience and Mental Health ETF$492 thousand
BINCiShares Flexible Income Active ETF$473 thousand
BINCiShares Flexible Income Active ETF$437 thousand
NTSIWisdomTree International Efficient Core Fund$358 thousand
CRBNiShares MSCI ACWI Low Carbon Target ETF$348 thousand
DFSIDimensional International Sustainability Core 1 ETF$299 thousand
BINCiShares Flexible Income Active ETF$243 thousand
LCTDBlackRock World ex U.S. Carbon Transition Readiness ETF$219 thousand
WCMEFirst Trust WCM Developing World Equity ETF$216 thousand
DWMFWisdomTree International Multifactor Fund$209 thousand
KOKUXtrackers MSCI Kokusai Equity ETF$178 thousand
PTINPacer Trendpilot International ETF$168 thousand
EFAXSPDR MSCI EAFE Fossil Fuel Free ETF$156 thousand
PABDiShares Paris-Aligned Climate Optimized MSCI World ex USA ETF$155 thousand
TEVA Analyst Ratings

TEVA Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
TEVA Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $TEVA stock a Buy, Sell, or Hold?

  • What is the price target for $TEVA stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

TEVA Top Shareholders
Shareholder
Shares Held
TEVA Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $TEVA stock?

  • Who owns the most shares of $TEVA stock?

  • What funds own $TEVA stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

TEVA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view TEVA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Bull Case vs Bear Case data is only available to Quiver Premium subscribers.

Back To Top